Cargando…

Quality of life, fatigue and local response of patients with unstable spinal bone metastases under radiation therapy - a prospective trial

BACKGROUND: To evaluate the local response according to stability after radiotherapy (RT) with a special focus on quality-of-life (QoL), fatigue, pain and emotional distress in patients with unstable spinal bone metastases. METHODS: In this prospective trial, 30 patients were treated from September...

Descripción completa

Detalles Bibliográficos
Autores principales: Rief, Harald, Heinhold, Maximiliane, Bruckner, Thomas, Schlampp, Ingmar, Förster, Robert, Welzel, Thomas, Bostel, Tilman, Debus, Jürgen, Rieken, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060071/
https://www.ncbi.nlm.nih.gov/pubmed/24917420
http://dx.doi.org/10.1186/1748-717X-9-133
Descripción
Sumario:BACKGROUND: To evaluate the local response according to stability after radiotherapy (RT) with a special focus on quality-of-life (QoL), fatigue, pain and emotional distress in patients with unstable spinal bone metastases. METHODS: In this prospective trial, 30 patients were treated from September 2011 until March 2013. The stability of osteolytic metastases in the thoracic and lumbar spine was evaluated on the basis of the Taneichi-score after three and six months. EORTC QLQ-BM22, EORTC QLQ-FA13, and QSC-R10 were assessed at baseline, and three months after RT. RESULTS: After 3 months, 25% (n = 6) and after 6 months 33.3% (n = 8) were classified as stable. QoL, fatigue, and emotional distress showed no difference over the course. The pain response 3 months after RT showed a significant difference (p < 0.001). Pathological fractures occurred in 8.3% of the patients (n = 2) within six months following RT. CONCLUSIONS: Our trial demonstrated that RT can improve stability in one third of patients over a 6-months period with unstable spinal metastases. Importantly, for these patients pain relief was detected but RT had no impact on QoL, fatigue, and emotional distress. TRIAL REGISTRATION: Clinical trial identifier NCT01409720.